



(86) Date de dépôt PCT/PCT Filing Date: 2001/10/09
(87) Date publication PCT/PCT Publication Date: 2002/05/16
(45) Date de délivrance/Issue Date: 2010/05/04
(85) Entrée phase nationale/National Entry: 2003/05/01
(86) N° demande PCT/PCT Application No.: US 2001/031386
(87) N° publication PCT/PCT Publication No.: 2002/038563
(30) Priorité/Priority: 2000/11/08 (US60/246,805)


(51) Cl.Int./Int.Cl. *C07D 471/04* (2006.01),
A61K 31/4985 (2006.01), *A61P 15/10* (2006.01),
A61P 9/00 (2006.01), *C07D 209/00* (2006.01),
C07D 221/00 (2006.01), *C07D 235/00* (2006.01),
C07D 241/00 (2006.01), *C07D 277/00* (2006.01),
C07D 307/00 (2006.01), *C07D 333/00* (2006.01),
C07D 471/14 (2006.01), *C07D 491/14* (2006.01),
C07D 495/14 (2006.01), *C07D 498/14* (2006.01),
C07D 513/14 (2006.01)

(72) Inventeurs/Inventors:
ORME, MARK W., US;
SAWYER, JASON SCOTT, US;
SCHULTZE, LISA M., US

(73) Propriétaire/Owner:

(54) Titre : DERIVES DE PYRADIZINDIONES CONDENSES, COMME INHIBITEURS DE PHOSPHODIESTERASES
(PDE)

(54) Title: CONDENSED PYRADIZINDIONE DERIVATIVES AS PDE INHIBITORS



(57) Abrégé/Abstract:

The present invention provides compounds of general structural formula (I) and use of the compounds, salts, and solvate thereof, as PDE inhibitors.



(73) Propriétaires(suite)/Owners(continued):LILLY ICOS LLC, US

(74) Agent: RIDOUT & MAYBEE LLP

Abstract

The present invention provides compounds of general structural formula (I) and use of the compounds, salts, and solvate thereof, as PDE inhibitors.


- 1 -

CONDENSED PYRADIZINDIONE DERIVATIVES AS PDE INHIBITORS**FIELD AND BACKGROUND OF THE INVENTION**

5 This invention relates to a series of compounds, to methods of preparing the compounds, to pharmaceutical compositions containing the compounds, and to their use as therapeutic agents. In particular, the invention relates to compounds that
 10 are potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5, and have utility in a variety of therapeutic areas wherein such inhibition is considered beneficial, including
 15 the treatment of cardiovascular disorders and erectile dysfunction.

DETAILED DESCRIPTION OF THE INVENTION

20 The present invention provides compounds of formula (I)



(I)

30 wherein R^0 , independently, is selected from the group consisting of halo, C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heteroaryl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-3} alkylenearyl, C_{1-3} alkyleneheteroaryl, Het, $C(=O)R^a$,


- 2 -

$\text{OC}(=\text{O})\text{OR}^a$, $\text{C}_{1-4}\text{alkyleneNR}^a\text{R}^b$, $\text{C}_{1-4}\text{alkyleneHet}$, $\text{C}_{1-4}\text{alkyleneC}(=\text{O})\text{OR}^a$, $\text{C}(=\text{O})\text{NR}^a\text{SO}_2\text{R}^b$, $\text{C}(=\text{O})\text{C}_{1-4}\text{alkyleneHet}$,
 $\text{C}(=\text{O})\text{NR}^a\text{R}^b$, $\text{C}(=\text{O})\text{NR}^a\text{C}_{1-4}\text{alkyleneOR}^b$, $\text{C}(=\text{O})\text{NR}^a\text{C}_{1-4}\text{alkyleneHet}$, OR^a , $\text{OC}_{1-4}\text{alkyleneC}(=\text{O})\text{OR}^a$, $\text{OC}_{1-4}\text{alkyleneNR}^a\text{R}^b$,
 5 $\text{OC}_{1-4}\text{alkyleneHet}$, $\text{OC}_{1-4}\text{alkyleneOR}^a$, $\text{OC}_{1-4}\text{alkyleneNR}^a\text{C}(=\text{O})\text{OR}^b$, NR^aR^b , $\text{NR}^a\text{C}_{1-4}\text{alkyleneNR}^a\text{R}^b$, $\text{NR}^a\text{C}(=\text{O})\text{R}^b$, $\text{NR}^a\text{C}(=\text{O})\text{NR}^a\text{R}^b$, $\text{N}(\text{SO}_2\text{C}_{1-4}\text{alkyl})_2$, $\text{NR}^a(\text{SO}_2\text{C}_{1-4}\text{alkyl})$, nitro,
 trifluoromethyl, trifluoromethoxy, cyano, $\text{SO}_2\text{NR}^a\text{R}^b$, SO_2R^a , SOR^a , SR^a , and OSO_2CF_3 ;

10 R^1 is selected from the group consisting of hydrogen, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{haloC}_{1-6}\text{alkyl}$, $\text{C}_{3-8}\text{cycloalkyl}$, $\text{C}_{3-8}\text{cycloalkylC}_{1-3}\text{alkyl}$, $\text{arylC}_{1-3}\text{alkyl}$, and heteroaryl $\text{C}_{1-3}\text{alkyl}$;

15 R^2 is selected from the group consisting of an optionally substituted monocyclic aromatic ring selected from the group consisting of benzene, thiophene, furan, and pyridine, and an optionally substituted bicyclic ring

20



25 wherein the fused ring A is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen;

30 R^3 is hydrogen or $\text{C}_{1-6}\text{alkyl}$, or R^1 and R^3 together form a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring;

- 3 -

fused ring B is a 5-, 6-, or 7-membered ring, saturated or partially or fully unsaturated, comprising carbon atoms and optionally one to three heteroatoms selected from oxygen, sulfur, and nitrogen;

R^a is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl, heteroaryl, aryl C_{1-3} alkyl, C_{1-3} alkylenearyl, $C(=O)OR^b$, $C(=O)N(R^b)_2$, C_{1-4} alkylene $N(R^b)_2$, CF_3 , OCF_3 , OR^b , $OC(=O)R^b$, OC_{1-4} alkylene $C(=O)OR^b$, C_{1-4} alkylene OC_{1-4} alkylene $C(=O)OR^b$, $C(=O)NR^bSO_2R^b$, $C(=O)C_{1-4}$ alkyleneHet, C_{2-6} alkenylene $N(R^b)_2$, $C(=O)NR^bC_{1-4}$ alkylene OR^b , $C(=O)NR^bC_{1-4}$ alkyleneHet, OC_{2-4} alkylene $N(R^b)_2$, OC_{1-4} alkylene $CH(OR^b)CH_2N(R^b)_2$, OC_{2-4} alkylene OR^b , OC_{2-4} alkylene $NR^bC(=O)OR^b$, $N(R^b)_2$, NR^bC_{1-4} alkylene $N(R^b)_2$, $NR^bC(=O)R^b$, $NR^bC(=O)N(R^b)_2$, $N(SO_2C_{1-4}alkyl)_2$, $NR^b(SO_2C_{1-4}alkyl)$, $SO_2N(R^b)_2$, OSO_2 trifluoromethyl, $C(=O)R^b$, C_{1-3} alkylene OR^b , CN , and C_{1-6} alkylene $C(=O)OR^b$;

R^b is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, aryl C_{1-3} alkyl, C_{1-3} alkylenearyl, heteroaryl, heteroaryl C_{1-3} alkyl, and C_{1-3} alkyleneheteroaryl;

q is 0, 1, 2, 3, or 4; and

pharmaceutically acceptable salts and hydrates thereof.

As used herein, the term "alkyl" includes straight chained and branched hydrocarbon groups containing the indicated number of carbon atoms, typically methyl, ethyl, and straight chain and branched propyl and butyl groups. The hydrocarbon group can contain up to 16 carbon atoms. The term "alkyl" includes "bridged alkyl," i.e., a C_6 - C_{16} bicyclic or polycyclic hydrocarbon group, for exam-

- 4 -

ple, norbornyl, adamantyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, or decahydronaphthyl. The term "cycloalkyl" is defined as a cyclic C₃-C₈ hydrocarbon group, e.g., cyclopropyl, cyclobutyl, cyclohexyl, and cyclopentyl.

The terms "alkenyl" and "alkynyl" are defined identically as "alkyl," except for containing a carbon-carbon double bond or carbon-carbon triple bond, respectively. "Cycloalkenyl" is defined similarly to cycloalkyl, except a carbon-carbon double bond is present in the ring.

The term "alkylene" refers to an alkyl group having a substituent. For example, the term "C₁₋₃alkylenearyl" refers to an alkyl group containing one to three carbon atoms, and substituted with an aryl group. The term "alkenylene" as used herein is similarly defined, and contains the indicated number of carbon atoms and a carbon-carbon double bond, and includes straight chained and branched alkenylene groups, like ethylenylene.

The term "halo" or "halogen" is defined herein to include fluorine, bromine, chlorine, and iodine.

The term "haloalkyl" is defined herein as an alkyl group substituted with one or more halo substituents, independently selected from fluoro, chloro, bromo, and iodo. Similarly, "halocycloalkyl" is defined as a cycloalkyl group having one or more halo substituents.

The term "aryl," alone or in combination, is defined herein as a monocyclic or polycyclic aromatic group, preferably a monocyclic or bicyclic aromatic group, e.g., phenyl or naphthyl. Unless

- 5 -

otherwise indicated, an "aryl" group can be unsubstituted or substituted, for example, with one or more, and in particular one to three, halo, alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl. Exemplary aryl groups include phenyl, naphthyl, tetrahydronaphthyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, and the like. The terms "arylC₁₋₃alkyl" and "heteroarylC₁₋₃alkyl" are defined as an aryl or heteroaryl group having a C₁₋₃alkyl substituent.

The term "heteroaryl" is defined herein as a monocyclic or bicyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and which can be unsubstituted or substituted, for example, with one or more, and in particular one to three, substituents, like halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl. Examples of heteroaryl groups include thienyl, furyl, pyridyl, oxazolyl, quinolyl, isoquinolyl, indolyl, triazolyl, isothiazolyl, isoxazolyl, imidazolyl, benzothiazolyl, pyrazinyl, pyrimidinyl, thiazolyl, and thiadiazolyl.

The term "Het" is defined as monocyclic, bicyclic, and tricyclic groups containing one or more heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. A "Het" group also can contain an oxo group (=O) attached to the ring. Nonlimiting examples of Het groups include 1,3-

- 6 -

dioxolane, 2-pyrazoline, pyrazolidine, pyrrolidine, piperazine, a pyrroline, 2H-pyran, 4H-pyran, morpholine, thiopholine, piperidine, 1,4-dithiane, and 1,4-dioxane.

5 The term "hydroxy" is defined as -OH.

 The term "alkoxy" is defined as -OR, wherein R is alkyl.

 The term "alkoxyalkyl" is defined as an alkyl group wherein a hydrogen atom has been replaced by an alkoxy group. The term "(alkylthio)-alkyl" is defined similarly as alkoxyalkyl, except a sulfur atom, rather than an oxygen atom, is present.

 The term "hydroxyalkyl" is defined as a hydroxy group appended to an alkyl group.

15 The term "amino" is defined as -NH₂, and the term "alkylamino" is defined as -NR₂, wherein at least one R is alkyl and the second R is alkyl or hydrogen.

 The term "acylamino" is defined as RC(=O)N, wherein R is alkyl or aryl.

20 The term "alkylthio" is defined as -SR, wherein R is alkyl.

 The term "alkylsulfinyl" is defined as R-SO₂, wherein R is alkyl.

25 The term "alkylsulfonyl" is defined as R-SO₃, wherein R is alkyl.

 The term "nitro" is defined as -NO₂.

 The term "trifluoromethyl" is defined as -CF₃.

30 The term "trifluoromethoxy" is defined as -OCF₃.

 The term "cyano" is defined as -CN.


- 7 -

Substituents R^0 can be positioned on a carbon atom or a heteroatom of ring B. In preferred embodiments, q is 0, or R^0 is selected from the group consisting of C_{1-6} alkyl, aryl, C_{1-3} alkylenearyl, C_{1-3} alkyleneheteroaryl, Het, OR^a , $C(=O)OR^a$, C_{1-4} alkylene-
 5 NR^aR^b , $C(=O)R^a$, NR^aR^b , C_{3-8} cycloalkyl, and $C(=O)NR^aR^b$.

In other preferred embodiments, R^1 is selected from the group consisting of hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkylene-
 10 C_{1-3} alkyl, aryl C_{2-3} alkyl, and heteroaryl C_{1-3} alkyl.

In a preferred group of compounds of formula (I), R^2 is represented by


15



20

wherein the bicyclic ring can represent, for example, naphthalene or indene, or a heterocycle, such as benzoxazole, benzothiazole, benzisoxazole, benzimidazole, quinoline, indole, benzothiophene, or benzofuran, or

25




30

wherein q is an integer 1 or 2, and G , independently, is $C(R^a)_2$, O , S , or NR^a . The bicyclic ring comprising the R^1 substituent typically is attached to



- 8 -

the rest of the molecule by a phenyl ring carbon atom.


In an especially preferred group of compounds of formula (I), R^2 is represented by an optionally substituted bicyclic ring



wherein q is 1 or 2, and G , independently, are CH_2 or O . Especially preferred R^2 substituents include



, and




Within this particular group of compounds, nonlimiting examples of substituents for the bicyclic ring include halogen (e.g., chlorine), C_{1-3} alkyl (e.g., methyl, ethyl, or *i*-propyl), OR^a (e.g., methoxy,

- 9 -


ethoxy, or hydroxy), CO_2R^a , halomethyl or halomethoxy (e.g., trifluoromethyl or trifluoromethoxy), cyano, nitro, and NR^aR^b .

5 Examples of ring B include, but are not limited to the following, including residues thereof:

10




cyclopentyl



cyclohexyl


15




cycloheptyl



cyclopentenyl




cyclohexenyl




1,3,5-cycloheptatrienyl

20




phenyl




furanyl

25




thienyl




2H-pyrrolyl

- 10 -




pyrrolyl

5




2-pyrrolynyl




3-pyrrolynyl

10




pyrrolidinyl




1,3-dioxolanyl

15




oxazolyl




thiazolyl

20




imidazolyl




2-imidazolinylyl

25




imidazolidinylyl

- 11 -




pyrazolyl

5




2-pyrazolinyl




pyrazolidinyl

10




isoxazolyl




isothiazolyl

15




1,2,3-oxadiazolyl




1,2,3-triazolyl

20




1,3,4-thiadiazolyl




3H-pyrrolyl

25




1,2-dithiolyl




1,3-dithiolyl

30




3H-1,2-oxathiolyl

- 12 -




1,2,4-oxadiazolyl


5




1,2,5-oxadiazolyl




1,3,4-oxadiazolyl




1,2,3,4-oxatriazolyl



1,2,3,5-oxatriazolyl




3H-1,2,3-dioxazolyl




1,2,4-dioxazolyl


10



1,3,2-dioxazolyl




1,3,4-dioxazolyl




5H-1,2,5-oxathiazolyl

15




1,3-oxathiolyl




2H-pyranyl

- 13 -

5




4H-pyranyl




pyridinyl

10




piperidinyl




1,4-dioxanyl

15




morpholinyl




1,4-dithianyl

20




thiomorpholinyl




pyridazinyl

25




pyrimidinyl




pyrazinyl

30


- 14 -




5 piperazinyl




1,3,5-triazinyl




10 1,3,5-trithianyl




2-pyronyl




15 4-pyronyl




1,2-dioxinyl




20 1,3-dioxinyl



1,2,4-triazinyl




30 1,2,3-triazinyl




4H-1,3-oxazinyl

- 15 -




2H-1,3-oxazinyl

5




6H-1,3-oxazinyl




6H-1,2-oxazinyl

10




4H-1,4-oxazinyl




2H-1,2-oxazinyl

15




1,4-oxazinyl




1,2,5-oxathiazinyl

20




p-isoxazinyl

25




o-isoxazinyl

30




1,2,6-oxathiazinyl

- 16 -




5

1,2,5-oxathiazinyl




10

1,4,2-oxadiazinyl




1,3,5,2-oxadiazinyl




15

azepinyl




oxepinyl



20

thiopinyl




1,2,4-diazepinyl

25

The R⁰ substituents can be bound to a carbon or a
 30 nitrogen atom of the B ring.

An especially preferred subclass of compounds within the general scope of formula (I) is represented by compounds of formula (II)

- 17 -



(II)

Compounds of formula (I) can contain one
 10 or more asymmetric center, and, therefore, can exist
 as stereoisomers. The present invention includes
 both mixtures and separate individual stereoisomers
 of the compounds of formula (I). Compounds of for-
 mula (I) also can exist in tautomeric forms, and the
 15 invention includes both mixtures and separate indi-
 vidual tautomers thereof.

Pharmaceutically acceptable salts of the
 compounds of formula (I) can be acid addition salts
 formed with pharmaceutically acceptable acids. Ex-
 20 amples of suitable salts include, but are not lim-
 ited to, the hydrochloride, hydrobromide, sulfate,
 bisulfate, phosphate, hydrogen phosphate, acetate,
 benzoate, succinate, fumarate, maleate, lactate,
 citrate, tartrate, gluconate, methanesulfonate,
 25 benzenesulfonate, and p-toluenesulfonate salts. The
 compounds of the formula (I) also can provide phar-
 maceutically acceptable metal salts, in particular
 alkali metal salts and alkaline earth metal salts,
 with bases. Examples include the sodium, potassium,
 30 magnesium, and calcium salts.

Compounds of the present invention are
 potent and selective inhibitors of cGMP-specific
 PDE5. Thus, compounds of formula (I) are of inter-

- 18 -

est for use in therapy, specifically for the treatment of a variety of conditions where selective inhibition of PDE5 is considered to be beneficial.

Phosphodiesterases (PDEs) catalyze the hydrolysis of cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). The PDEs have been classified into at least seven isoenzyme families and are present in many tissues (J.A. Beavo, *Physiol. Rev.*, 75, p. 725 (1995)).

PDE5 inhibition is a particularly attractive target. A potent and selective inhibitor of PDE5 provides vasodilating, relaxing, and diuretic effects, all of which are beneficial in the treatment of various disease states. Research in this area has led to several classes of inhibitors based on the cGMP basic structure (E. Sybertz et al., *Expert. Opin. Ther. Pat.*, 7, p. 631 (1997)).

The biochemical, physiological, and clinical effects of PDE5 inhibitors therefore suggest their utility in a variety of disease states in which modulation of smooth muscle, renal, hemostatic, inflammatory, and/or endocrine function is desirable. The compounds of formula (I), therefore, have utility in the treatment of a number of disorders, including stable, unstable, and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, malignant hypertension, congestive heart failure, myocardial infarction, angioplasty, acute respiratory distress syndrome, acute and chronic renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g., postpercutaneous transluminal coronary or carotid angioplasty, or post-bypass surgery graft stenosis), peripheral vascular disease, vascu-

- 19 -

lar disorders, such as Raynaud's disease, thrombocythemia, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, peptic ulcer, male erectile dysfunction, female sexual dysfunction, diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome) and pheochromocytoma.

An especially important use is the treatment of male erectile dysfunction, which is one form of impotence and is a common medical problem. Impotence can be defined as a lack of power, in the male, to copulate, and can involve an inability to achieve penile erection or ejaculation, or both. The incidence of erectile dysfunction increases with age, with about 50% of men over the age of 40 suffering from some degree of erectile dysfunction.

In addition, a further important use is the treatment of female arousal disorder. Female arousal disorders are defined as a recurrent inability to attain or maintain an adequate lubrication/swelling response of sexual excitement until completion of sexual activity. The arousal response consists of vasocongestion in the pelvis, vaginal lubrication, and expansion and swelling of external genitalia.

It is envisioned, therefore, that compounds of formula (I) are useful in the treatment of male erectile dysfunction and female arousal disorder. Thus, the present invention concerns the use of compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture

- 20 -

of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal and arousal disorder in a female animal, including humans.

5 The term "treatment" includes preventing, lowering, stopping, or reversing the progression or severity of the condition or symptoms being treated. As such, the term "treatment" includes both medical therapeutic and/or prophylactic administration, as
10 appropriate.

 It also is understood that "a compound of formula (I)," or a physiologically acceptable salt or solvate thereof, can be administered as the neat compound, or as a pharmaceutical composition con-
15 taining either entity.

 Although compounds of the invention are envisioned primarily for the treatment of sexual dysfunction in humans, such as male erectile dys-
20 function and female arousal disorder, they also can be used for the treatment of other disease states.

 A further aspect of the present invention, therefore, is providing a compound of formula (I) for use in the treatment of stable, unstable, and variant (Prinzmetal) angina, hypertension, pulmonary
25 hypertension, malignant hypertension, chronic obstructive pulmonary disease, congestive heart failure, myocardial infarction, carotid angioplasty, acute respiratory disease syndrome, acute and chronic renal failure, athero-
 sclerosis, conditions of reduced blood vessel paten-
 cy (e.g., post-PTCA or post-bypass graft stenosis),
30 peripheral vascular disease, vascular disorders such as Raynaud's disease, thrombocythemia, inflammatory diseases, prophylaxis of myocardial infarction, prophylaxis of stroke, stroke, bronchitis, chronic

- 21 -

asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, diseases characterized by disorders of gut motility (e.g., IBS) or pheochromocytoma.

According to another aspect of the present invention, there is provided the use of a compound of formula (I) for the manufacture of a medicament for the treatment of the above-noted conditions and disorders.

In a further aspect, the present invention provides a method of treating the above-noted conditions and disorders in a human or nonhuman animal body which comprises administering to said body a therapeutically effective amount of a compound of formula (I).

Compounds of the invention can be administered by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, transurethral, nasal, topical, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, and intracoronary) administration. Parenteral administration can be accomplished using a needle and syringe, or using a high pressure technique, like POWDERJECT™.

Oral administration of a compound of the invention is the preferred route. Oral administration is the most convenient and avoids the disadvantages associated with other routes of administration. For patients suffering from a swallowing disorder or from impairment of drug absorption after oral administration, the drug can be administered parenterally, e.g., sublingually or buccally.

- 22 -

Compounds and pharmaceutical compositions suitable for use in the present invention include those wherein the active ingredient is administered in an effective amount to achieve its intended purpose. More specifically, a "therapeutically effective amount" means an amount effective to prevent development of, or to alleviate the existing symptoms of, the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

A "therapeutically effective dose" refers to that amount of the compound that results in achieving the desired effect. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD₅₀ and ED₅₀. Compounds which exhibit high therapeutic indices are preferred. The data obtained from such data can be used in formulating a dosage range for use in humans. The dosage of such compounds preferably lies within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized.

The exact formulation, route of administration, and dosage can be chosen by the individual

- 23 -

physician in view of the patient's condition. Dosage amount and interval can be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the therapeutic effects.

5 The amount of composition administered is dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician.

10 Specifically, for administration to a human in the curative or prophylactic treatment of the conditions and disorders identified above, oral dosages of a compound of formula (I) generally are about 0.5 to about 1000 mg daily for an average
15 adult patient (70 kg). Thus, for a typical adult patient, individual tablets or capsules contain 0.2 to 500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several
20 times per day. Dosages for intravenous, buccal, or sublingual administration typically are 0.1 to 500 mg per single dose as required. In practice, the physician determines the actual dosing regimen which is most suitable for an individual
25 patient, and the dosage varies with the age, weight, and response of the particular patient. The above dosages are exemplary of the average case, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope
30 of this invention.

 For human use, a compound of the formula (I) can be administered alone, but generally is administered in admixture with a pharmaceutical car-

- 24 -

rier selected with regard to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions for use in accordance with the present invention thus can be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate processing of compounds of formula (I) into preparations which can be used pharmaceutically.

These pharmaceutical compositions can be manufactured in a conventional manner, e.g., by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of a compound of the present invention is administered orally, the composition typically is in the form of a tablet, capsule, powder, solution, or elixir.

When administered in tablet form, the composition can additionally contain a solid carrier, such as a gelatin or an adjuvant. The tablet, capsule, and powder contain about 5% to about 95% compound of the present invention, and preferably from about 25% to about 90% compound of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, or oils of animal or plant origin can be added. The liquid form of the composition can further contain physiological saline solution, dextrose or other saccharide solutions, or glycols. When administered in liquid form, the composition contains about 0.5% to about 90% by weight of a compound of the present invention, and

- 25 -

preferably about 1% to about 50% of a compound of the present invention.

When a therapeutically effective amount of a compound of the present invention is administered by intravenous, cutaneous, or subcutaneous injection, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred composition for intravenous, cutaneous, or subcutaneous injection typically contains, in addition to a compound of the present invention, an isotonic vehicle.

For oral administration, the compounds can be formulated readily by combining a compound of formula (I) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the present compounds to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by adding a compound of formula (I) with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers and cellulose preparations. If desired, disintegrating agents can be added.

For administration by inhalation, compounds of the present invention are conveniently delivered in the form of an aerosol spray presenta-

- 26 -

tion from pressurized packs or a nebulizer, with the use of a suitable propellant. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges, e.g., gelatin, for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative. The compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulation agents such as suspending, stabilizing, and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension. Optionally, the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds and allow for the preparation of highly concentrated solutions. Alternatively, a present composition can be in powder form for con-

- 27 -

stitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

Compounds of the present invention also can be formulated in rectal compositions, such as suppositories or retention enemas, e.g., containing conventional suppository bases. In addition to the formulations described previously, the compounds also can be formulated as a depot preparation. Such long-acting formulations can be administered by im-plantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Many of the compounds of the present invention can be provided as salts with pharmaceutically compatible counterions. Such pharmaceutically acceptable base addition salts are those salts that retain the biological effectiveness and properties of the free acids, and that are obtained by reaction with suitable inorganic or organic bases.

In particular, a compound of formula (I) can be administered orally, buccally, or sublingually in the form of tablets containing excipients, such as starch or lactose, or in capsules or ovules, either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. Such liquid preparations can be prepared with pharmaceutically acceptable additives, such as suspending agents. A compound also can be injected parenterally, for example,

- 28 -

intravenously, intramuscularly, subcutaneously, or intracoronarily. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which can contain other substances, for example, salts or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.

For veterinary use, a compound of formula (I) or a nontoxic salt thereof, is administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal.

Thus, the invention provides in a further aspect a pharmaceutical composition comprising a compound of the formula (I), together with a pharmaceutically acceptable diluent or carrier therefor. There is further provided by the present invention a process of preparing a pharmaceutical composition comprising a compound of formula (I), which process comprises mixing a compound of formula (I), together with a pharmaceutically acceptable diluent or carrier therefor.

In a particular embodiment, the invention includes a pharmaceutical composition for the curative or prophylactic treatment of erectile dysfunction in a male animal, or arousal disorder in a female animal, including humans, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

- 29 -


Compounds of formula (I) can be prepared by any suitable method known in the art, or by the following processes which form part of the present invention. In the methods below, R^0 , R^1 , R^2 , and R^3 are as defined in structural formula (I) above. Generally, compounds of structural formula (I) can be prepared according to the following synthetic schemes.

In particular, using an appropriately substituted 2-arylethylamine or 2-heteroarylethylamine, a compound of general structural formula (I) can be prepared using the methods outlined below. Methods A-C are examples of synthetic routes to the diketopiperazine-tetrahydroisoquinolines and diketopiperazine-tetrahydroimidazopyridines of formula (I). However, additional synthetic routes exist for the synthesis of tetrahydroisoquinolines. For example, see, M.D. Rozwadowska, *Heterocycles*, 39, 903 (1994); M. Shamma, *Isoquinoline Alkaloids, Chemistry and Pharmacology*, Academic Press: New York (1972); and T. Kametani, *The Chemistry of the Isoquinoline Alkaloids*, Elsevier, Amsterdam (1969).

- 30 -



GENERAL METHOD A

5





10

15



or




(I)

20

- 31 -


The compounds of general structural formula (III) can be prepared, for example, by the Pictet-Spengler reaction. See, W. Whaley et al., *Org. React*, 6, 151-206 (1951); S.M. Hutchins et al., *Tetrahedron Lett.*, 37, 4865 (1996); R.D. Cox et al., *Chem. Rev.*, 95, 1797 (1995); and A. Yokoyama et al., *J. Org. Chem.*, 64, 611 (1999). A substituted aryl-ethylamine or heteroarylethylamine ester is reacted with an aldehyde to provide a compound (III). The resulting secondary amine (III) then is treated with either an amino acid or an acid halide under suitable acylation conditions to form an amide-ester. Ring cyclization to form a compound of structural formula (I) is accomplished by an intramolecular amine attack on the ester. Compounds (I) also can be derived from a suitable side chain bearing a leaving group (e.g., compound (IV)) that reacts with a primary amine.

GENERAL METHOD B




- 32 -

5



(V)



(VI)

(I)



10

15


20

Alternatively, a compound (I) can be prepared by first reacting an arylethylamine or hetero-arylethylamine with an amino acid under typical peptide coupling conditions to form an amide (V). Ring cyclization to form a diketopiperazine (VI) is accomplished by intramolecular amine attack on the ester. The resulting piperazine (VI) is subjected to a condensation reaction with an aldehyde under modified Pictet-Spengler conditions to provide a compound of structural formula (I). For a discussion of the modified Pictet-Spengler reaction, see T.A. Miller et al., *Bioorg. Med. Chem. Lett.*, 8, 1065 (1998); A. Previero et al., *Canadian J. of Chemistry*, 46, 3404 (1968); and P. Ducrot et al., *Tet. Lett.*, 40, 9037 (1999).

- 33 -

GENERAL METHOD C


(VII)




(VIII)

30

- 34 -




10



15

or

20



25



30

A tetrahydroisoquinoline skeleton also can be constructed using the Bischler-Napieralski reaction, which includes a cyclodehydration of an acylated β -arylethylamine. P_2O_5 or POCl_3 are the most typical cyclization reagents. See, W.M. Whaley et al., *Org. React*, VI, 74-150 (1951); W.D.F. Meutermans et al., *Tetrahedron Lett.*, 36, 7709 (1995); A. Ishida et al., *Chem. Pharm. Bull.*, 34, 1995 (1986); and A.K. Saxena et al., *Indian J. Chem.*, 13, 230

- 35 -

(1975). Reduction of the resulting imine (VIII), with NaBH_4 , for example, provides a 1,2,3,4-tetrahydro- β -carboline (IX).

5 A modified method C avoids racemisation because the amine first is acylated, then converted to the thioamide, for example, with Lawesson's reagent. Treatment of the thioamide with an alkyl halide or acyl halide provides an iminium halide (XI). Reduction of the crude intermediate (XII) with NaBH_4 at reduced temperature stereoselectively
10 leads to the tetrahydroisoquinoline (IX).




15


20

- 36 -


5




10



15



20



25

- 37 -

In the synthesis of compounds of structural formula (I), protecting compounds and protecting groups, like benzyl chloroformate and trichloroethyl chloroformate, which are well known to persons skilled in the art, can be used. Such protecting groups are disclosed, for example, in T.W. Greene et al. "Protective Groups in Organic Synthesis, Third Edition," John Wiley and Sons, Inc., NY, NY (1999). These protecting groups are removed in the final steps of the synthesis under basic, acidic, or hydrogenolytic conditions which are readily apparent to those skilled in the art. By employing appropriate starting materials, and manipulation and protection of chemical functionalities, synthesis of compounds of structural formula (I) not specifically set forth herein can be accomplished by methods analogous to the schemes set forth above.

Compounds of formula (I) can be converted to other compounds of formula (I). Thus, for example, when a compound contains a substituted aromatic ring, it is possible to prepare another suitably substituted compound of formula (I). Examples of appropriate interconversions include, but are not limited to, OR^b to hydroxy by suitable means (e.g., using an agent such as BBr₃, SnCl₂, or a palladium catalyst, such as palladium-on-carbon), or amino to substituted amino, such as alkylamine, using standard acylating or sulfonylating conditions.

Compounds of formula (I) can be prepared by the method above as individual stereoisomers or as a racemic mixture. Individual stereoisomers of the compounds of the invention can be prepared from racemates by resolution using methods known in the

- 38 -

art for the separation of racemic mixtures into their constituent stereoisomers, for example, using HPLC on a chiral column, such as HypersilTM naphthyl urea, or using separation of salts of stereoisomers.

5 Compounds of the invention can be isolated in association with solvent molecules by crystallization from, or evaporation of, an appropriate solvent.

The pharmaceutically acceptable acid addition salts of the compounds of formula (I) that contain a basic center can be prepared in a conventional manner. For example, a solution of the free base can be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts can be obtained in an analogous manner by treating a solution of a compound of formula (I) with a suitable base. Both types of salt can be formed or interconverted using ion-exchange resin techniques. Thus, according to a further aspect of the invention, a method for preparing a compound of formula (I) or a salt or solvate (e.g., hydrate) is provided, followed by (i) salt formation, or (ii) solvate (e.g., hydrate) formation.

10
15
20
25

The following abbreviations are used hereafter in the accompanying examples: rt (room temperature), min (minute), h (hour), g (gram), mmol (millimole), m.p. (melting point), eq (equivalents), L (liter), mL (milliliter), μ L (microliters), Et₂O (diethyl ether), CH₂Cl₂ (dichloromethane), MeOH (methanol), Et₃N (triethylamine), EtOAc (ethyl acetate), AcOH (acetic acid), HCl (hydrochloric acid),

30


- 39 -

MeNH₂ (methylamine), TFA (trifluoroacetic acid), IPA (isopropyl alcohol), aq (aqueous), NaCl (sodium chloride), Na₂SO₄ (sodium sulfate), NaHCO₃ (sodium bicarbonate), and THF (tetrahydrofuran).

5 The following illustrates specific examples of compounds of structural formula (I) and synthetic routes to compounds (I).

Preparation of Example 1

10 (+-, cis)-4-Benzo[1,3]dioxol-5-yl-7-methyl-3,4,6,7,8a,9-hexahydro-1,3,4a,7-tetraazacyclopenta[b]naphthalene-5,8-dione hydrochloride




30 Example 1 was prepared from D-histidine monohydrochloride monohydrate by the following synthetic scheme. Also see S.M. Hutchins et al., *Tet. Letters*, 37, 4865-4868 (1996).


35

- 40 -

5



10




15

Intermediate 1


20

25



Intermediate 2

- 41 -



**Preparation of D-Histidine Methyl
Ester Monohydrochloride (Intermediate 1)**

5

Thionyl chloride (29.37 g, 18.0 mL, 246.9 mmol) was added dropwise to a suspension of D-histidine monohydrochloride monohydrate (10.35 g, 49.37 mmol) in anhydrous MeOH (150 mL) at 0°C under a nitrogen blanket. The resulting mixture was slowly warmed to room temperature, then stirred for 24 hours. The solvent then was removed under reduced pressure to provide a white solid. The residue was suspended in Et_2O , which was collected by filtration. Analysis of the resulting solid by ^1H NMR showed it to be a mixture of starting material and Intermediate 1. The thionyl chloride treatment was repeated three times as described above to yield a white solid (11.74 g, 100%) with less than 10% starting material present: ^1H NMR (300 MHz, CDCl_3): δ 9.07 (d, $J=1.2$ Hz, 1H), 8.7-9.1 (bs, 1H), 7.52 (s, 1H), 4.47 (t, $J=7.1$ Hz, 1H), 3.73 (s, 3H), 3.32-3.29 (m, 2H).

25

- 42 -

Preparation of (+/-)-cis- β -carboline
(Intermediate 2)

5 A suspension of Intermediate 1 (3.24 g, 14.59 mmol) and piperonal (2.63 g, 17.51 mmol) in pyridine (70 mL) was warmed to 100°C, then stirred for 4 hours under a nitrogen blanket. The resulting orange solution was cooled to room temperature and
10 concentrated *in vacuo*. The crude product was purified by column chromatography (silica gel, 0-20% MeOH/CH₂Cl₂) to yield 1.72 g (39.2%) of an orange solid: TLC R_f (10% MeOH/CH₂Cl₂)=0.39; ¹H NMR (300 MHz, CDCl₃): δ 8.99 (s, 1H), 7.07 (s, 1H), 7.03 (s, 2H), 6.09 (s, 2H), 5.71 (s, 1H), 4.70-4.65 (m, 1H),
15 3.80 (s, 3H), 3.36-3.25 (m, 2H): MS (API) m/z 302 (M+H). The *trans* carboline was also eluted from the column, but not in pure form: TLC R_f (10% MeOH/-CH₂Cl₂)=0.34.

20

Preparation of (+/-)-cis-2-chloroacetyl- β -
carboline (Intermediate 3)

25 Chloroacetyl chloride (0.6 mL, 7.4 mmol) was added dropwise to a mixture of Intermediate 2 (1.72 g, 5.7 mmol) and Et₃N (1.6 mL, 11.4 mmol) in THF (40 mL) and water (5 mL) at 0°C under a nitrogen blanket. The resulting mixture was warmed to room
30 temperature, then stirred for about 1 hour. The reaction was quenched with 1N HCl (2 mL), then concentrated *in vacuo*. The crude product was purified by column chromatography (silica gel, 5-10% MeOH/-CH₂Cl₂) to provide 0.49 g (22.8%) of a light yellow

- 43 -

solid: TLC R_f (3% EtOAc/ CH_2Cl_2)=0.43; MS (API) m/z 378 (M+H).


Preparation of Example 1

5


A mixture of crude Intermediate 3 (0.49 g, 1.29 mmol), 40% MeNH₂ in water (1.10 mL, 6.48 mmol) in THF (20 mL) was heated at 45°C under a nitrogen blanket for 45 minutes. The reaction was incomplete. Water (2 mL) was added to give a clear two-phase mixture. After an additional 20 minutes, the resulting solution was cooled to room temperature, quenched with concentrated HCl (4 mL), and concentrated to remove THF. The resulting slurry was filtered, and the solid was washed forward with water and acetone. The product was obtained as a white solid (0.16 g, 36%) after drying at 45°C under vacuum: mp 227-230°C; TLC R_f (10% MeOH/ CH_2Cl_2)=0.20; ¹H NMR (300 MHz, DMSO- d_6): δ 14.7 (bs, 2H), 8.94 (s, 1H), 6.80-6.91 (m, 3H), 6.00 (s, 1H), 5.96 (s, 2H), 4.35 (dd, J =4.3 Hz, J =11.2 Hz, 1H), 4.13 (d, J =17.1 Hz, 1H), 3.97 (d, J =17.6 Hz, 1H), 3.60 (bs, 1H), 3.41 (dd, J =4.6 Hz, J =16.4 Hz, 1H), 3.17-3.27 (m, 1H), 2.90 (s, 3H); MS (API) m/z 341 (M+H); $[\alpha]_D^{25^\circ\text{C}}$ =no observed rotation (c =0.15, DMSO). Anal. Calcd for C₁₇H₁₇N₄O₄•HCl•0.4 H₂O: C, 53.17; H, 4.67; N, 14.59. Found: C, 53.26; H, 4.54; N, 14.52. The relative stereochemistry of the product was confirmed to be the *cis* isomer by NOE difference experiments (DMSO- d_6): positive NOE enhancements from the C12a proton at 4.35 ppm to the C4 proton at 6.00 ppm.

30

- 44 -




Preparation of Example 2

The compound of Example 2 can be prepared in a manner similar to Example 1:


Preparation of Example 3

The compound of Example 3 can be prepared by the following synthetic sequence.

- 45 -




- 46 -



Preparation of Example 4 and 5


Examples 4 and 5 can be prepared by the synthetic sequence of Example 3.





X=O, S

Example 4 (X=O)
Example 5 (X=S)

- 47 -


Preparation of Example 6

Example 6 can be prepared by the following synthetic sequence.




- 48 -

5



10


15




20

Preparation of Example 7



Example 7 can be prepared by the synthetic sequence of Example 6.




- 49 -

Preparation of Example 8

The compound of Example 8 can be prepared by the following synthetic sequence.




- 50 -



20 Preparation of Example 9


Example 9 can be prepared by the synthetic sequence of Example 8.




- 51 -

Preparation of Example 10



(6R,11aS) -6-Benzo[1,3]dioxol-5-yl-8,9-dimethoxy-
2-methyl-2,3,11,11a-tetrahydro-6H-pyrazino-
[1,2-b]isoquinoline-1,4-dione




Tetrahydroisoquinoline analog Example 10 was prepared from 3-(3,4-dimethoxyphenyl)-L-alanine 1 as depicted in the following synthetic scheme. See, A.K. Saxena et al., *Indian J. Chem.*, 13, 230-237 (1975).



- 52 -




Intermediate 5.




Intermediate 6


- 53 -



Intermediate 7



Intermediate 8



- 54 -

Preparation of (S)-2-Amino-3-(3,4-dimethoxy-
phenyl)propionic acid methyl ester
(Intermediate 4)

5 Thionyl chloride (3.2 g, 2.0 mL, 26.8
mmol) was added dropwise to a suspension 3-(3,4-
dimethoxyphenyl)-L-alanine 1 (2.0 g, 8.9 mmol) in
anhydrous MeOH (50 mL) at 0°C under a nitrogen blan-
10 ket. The mixture was slowly warmed to room tempera-
ture, then stirred for 72 hours. The solvent was
removed under reduced pressure to provide a solid.
The crude product was taken up in CH₂Cl₂, then washed
with saturated NaHCO₃ and saturated NaCl. The organ-
15 ic layer was dried over anhydrous Na₂SO₄, filtered
and concentrated to yield a light brown oil (1.97 g,
93%).

20 Preparation of 2-[(1-Benzo[1,3]dioxol-5-yl-
methanoyl)amino]-3-(3,4-dimethoxyphenyl)-
propionic acid methyl ester (Intermediate 5)

Piperonyl chloride (1.90 g, 2.14 mmol)
25 was added portionwise to a mixture of crude Interme-
diate 4 (1.90 g, 7.94 mmol) and Et₂O (2.5 mL, 18.3
mmol) in CH₂Cl₂ (40 mL) at 0°C under a nitrogen blan-
ket. The resulting mixture was stirred for 4 hours
at 0°C, then warmed to room temperature. The reac-
30 tion was diluted with CH₂Cl₂ (50 mL) and was washed
with 0.2 M HCl (2 x 40 mL), saturated NaHCO₃ (40 mL),
and saturated NaCl (40 mL). The solution was dried
over anhydrous Na₂SO₄, filtered, and concentration *in*
vacuo to provide a white solid. The solid was col-
35 lected by filtration and washed with 20% EtOAc/-
hexane to yield 3.69 g (100%) of Intermediate 5.

- 55 -

TLC R_f (5% MeOH/CH₂Cl₂)=0.57; ¹H NMR (300 MHz, CDCl₃):
δ 8.62 (d, J=7.7 Hz, 1H), 7.42 (dd, J=1.7 Hz, J=8.13
Hz, 1H), 7.36 (d, J=1.6 Hz, 1H), 6.98 (d, J=8.2 Hz,
1H), 6.91 (d, J=1.7 Hz, 1H), 6.77-6.85 (m, 2H), 6.09
5 (s, 2H), 4.58 (m, 1H), 3.69 (s, 6H), 3.64 (s, 3H),
2.95-3.10 (m, 2H).

10 Preparation of 1-Benzo[1,3]dioxol-5-yl-6,7-
dimethoxy-3,4,4a,8a-tetrahydroisoquinoline-
3-carboxylic acid methyl ester (Intermediate 6)

A mixture of Intermediate 5 (3.074 g, 7.94
mmol), and POCl₃ (15 mL) was heated at 120°C under a
15 nitrogen blanket for 1.5 hours. The mixture was
cooled to room temperature, then poured onto ice
water (100 mL) and extracted with EtOAc (2 x 200
mL). The combined organic layers were dried over
anhydrous Na₂SO₄, filtered, and concentrated to a tan
20 foam. The crude product was purified by column
chromatography on silica gel using 1% Et₃N in 5%
MeOH/CH₂Cl₂ to provide Intermediate 6 as a beige foam
(1.60 g, 55%): TLC R_f (5% MeOH/CH₂Cl₂)=0.55; ¹H NMR
(300 MHz, CDCl₃) δ: 7.17 (d, J=1.6 Hz, 1H), 7.11
25 (dd, J=8.0 Hz, J=1.6 Hz, 1H), 6.85 (m, 2H), 6.79 (s,
1H), 6.01 (d, J=1.1 Hz, 2H), 4.30 (dd, J=12.3 Hz,
J=6.3 Hz, 1H), 3.95 (s, 3H), 3.81 (s, 3H), 3.77 (s,
3H), 2.91-3.08 (m, 2H); MS (API) m/z 370 (M+H).

30 Preparation of 1-Benzo[1,3]dioxol-5-yl-6,7-
dimethoxy-1,2,3,4,4a,8a-hexahydroisoquinoline-
3-carboxylic acid methyl ester (Intermediate 7)

35 A solution of Intermediate 6 (1.5 g, 4.06
mmol) in MeOH (60 mL) was cooled to 0°C and stirred

- 56 -

under a nitrogen blanket. Sodium borohydride (154 mg) was added, and the resulting mixture was stirred for 2 hours. The reaction mixture then was concentrated *in vacuo*, during which time a white solid precipitated. The solid was triturated with MeOH (20 mL), collected by filtration, and dried to give 0.82 g (54%) of Intermediate 7: TLC R_f (90:10:1 $\text{CH}_2\text{Cl}_2/\text{EtOAc}/\text{MeOH}$)=0.33; ^1H NMR (300 MHz, CDCl_3) δ : 6.84 (dd, $J=7.8$ Hz, $J=1.6$ Hz, 1H), 6.76-6.79 (m, 2H), 6.62 (s, 1H), 6.21 (s, 1H), 5.95 (dd, $J=3.4$ Hz, $J=1.1$ Hz, 2H), 5.02 (bs 1H), 3.82-3.86 (m, 1H), 3.86 (s, 3H), 3.78 (s, 3H), 3.64 (s, 3H), 3.01-3.14 (m, 2H), 2.41 (bs, NH); MS (API) m/z 372 (M+H).

Preparation of 1-Benzo[1,3]dioxol-5-yl-2-(2-chloroethanoyl)-6,7-dimethoxy-1,2,3,4,4a,8a-hexahydroisoquinoline-3-carboxylic acid methyl ester (Intermediate 8)

Chloroacetyl chloride (0.23 mL, 2.88 mmol) was added dropwise to a mixture of Intermediate 7 (0.82 g, 2.21 mmol) and Et_3N (0.71 mL, 5.09 mmol) in CH_2Cl_2 (15 mL) at 0°C under a nitrogen blanket. The resulting mixture was warmed to room temperature and stirred for about 0.5 hour. The reaction was quenched with 1 N HCl (2 mL), and diluted with CH_2Cl_2 (50 mL) and water (10 mL). The layers were separated and the organic was washed with saturated NaCl and dried over anhydrous Na_2SO_4 . Filtration and concentration *in vacuo* afforded Intermediate 8 (1.5 g), which was used without further purification. TLC R_f (10% $\text{EtOAc}/\text{CH}_2\text{Cl}_2$)=0.55; MS (API) m/z 448 (M+H), 472 (M+Na).

- 57 -


Preparation of Example 10

A mixture of crude Intermediate 8 (0.99 g, 2.21 mmol), 40% MeNH₂ in water (1.8 mL, 22.2 mmol) in THF (15 mL) was heated at 45°C under a nitrogen blanket for 1.5 hours. The reaction was quenched with concentrated HCl until the pH was acidic. The mixture was concentrated to remove THF. To the resulting slurry was added 3:1 water:MeOH (30 mL). The solid was collected by filtration, washed with water and Et₃O (2 x 10 mL), and dried to provide Example 10 as a white solid (0.74 g, 82%): mp 235-236°C; TLC R_f (10% EtOAc/CH₂Cl₂)=0.14; ¹H NMR (300 MHz, DMSO-d₆) δ: 7.21 (s, 1H), 6.99 (s, 1H), 6.74-6.77 (m, 2H), 6.54 (dd, J=1.2 Hz, J=7.4 Hz, 1H), 6.29 (s, 1H), 5.94 (d, J=6.3 Hz, 2H), 4.17-4.28 (m, 2H), 3.93 (d, J=16.5 Hz, 1H), 3.76 (s, 3H), 3.74 (s, 3H), 3.17 (dd, J=3.2 Hz, J=3.9 Hz, 1H), 2.95 (s 3H), 2.72 (dd, J=2.7 Hz, J=12.9 Hz, 1H); MS (API) m/z 411 (M+H), 433 (M+Na); [α]_D^{25°C}=no observed rotation (c=0.43, DMSO). Anal. Calcd for C₂₂H₂₂N₂O₆•0.15 H₂O: C, 63.96; H, 5.44; N, 6.78. Found: C, 63.88; H, 5.45; N, 6.84. The relative stereochemistry of the product was confirmed to be the *trans* isomer by NOE difference experiments (DMSO-d₆): no positive NOE enhancements from the C6 proton at 3.93 ppm to the C11 proton at 6.29 ppm.

Preparation of Example 11

The compound of Example 11 can be prepared by the synthetic sequence of Example 10.

- 58 -



Compounds of the present invention can be formulated into tablets for oral administration. For example, a compound of formula (I) can be formed into a dispersion with a polymeric carrier by the coprecipitation method set forth in WO 96/38131.

The coprecipitated dispersion can be blended with excipients, then pressed into tablets, which optionally are film-coated.

The compounds of structural formula (I) were tested for an ability to inhibit PDE5. The ability of a compound to inhibit PDE5 activity is related to the IC_{50} value for the compound, i.e., the concentration of inhibitor required for 50% inhibition of enzyme activity. The IC_{50} value for compounds of structural formula (I) were determined using recombinant human PDE5.

The compounds of the present invention typically exhibit an IC_{50} value against recombinant human PDE5 of less than about 50 μM , and preferably less than about 25 μM , and more preferably less than about 15 μM . The compounds of the present invention typically exhibit an IC_{50} value against recombinant

- 59 -

human PDE5 of less than about 1 μM , and often less than about 0.05 μM . To achieve the full advantage of the present invention, a present PDE5 inhibitor has an IC_{50} of about 0.1 nM to about 15 μM .

5 The production of recombinant human PDEs and the IC_{50} determinations can be accomplished by well-known methods in the art. Exemplary methods are described as follows:

10 EXPRESSION OF HUMAN PDEs

Expression in *Saccharomyces cerevisiae* (Yeast)

 Recombinant production of human PDE1B,
15 PDE2, PDE4A, PDE4B, PDE4C, PDE4D, PDE5, and PDE7 was carried out similarly to that described in Example 7 of U.S. Patent No. 5,702,936,

 except that the yeast transformation vector employed, which is derived from the basic ADH2
20 plasmid described in Price et al., *Methods in Enzymology*, 185, pp. 308-318 (1990), incorporated yeast ADH2 promoter and terminator sequences and the *Saccharomyces cerevisiae* host was the protease-deficient strain BJ2-54 deposited on August 31, 1998
25 with the American Type Culture Collection, Manassas, Virginia, under accession number ATCC 74465. Transformed host cells were grown in 2X SC-leu medium, pH 6.2, with trace metals, and vitamins. After 24 hours, YEP medium-containing glycerol was added to a
30 final concentration of 2X YET/3% glycerol. Approximately 24 hr later, cells were harvested, washed, and stored at -70°C .

- 60 -

HUMAN PHOSPHODIESTERASE PREPARATIONSPhosphodiesterase Activity Determinations

5 Phosphodiesterase activity of the preparations was determined as follows. PDE assays utilizing a charcoal separation technique were performed essentially as described in Loughney et al. (1996). In this assay, PDE activity converts [32P]cAMP or
10 [32P]cGMP to the corresponding [32P]5'-AMP or [32P]5'-GMP in proportion to the amount of PDE activity present. The [32P]5'-AMP or [32P]5'-GMP then was quantitatively converted to free [32P]phosphate and unlabeled adenosine or guanosine by the action
15 of snake venom 5'-nucleotidase. Hence, the amount of [32P]phosphate liberated is proportional to enzyme activity. The assay was performed at 30°C in a 100 µL reaction mixture containing (final concentrations) 40 mM Tris HCl (pH 8.0), 1 µM ZnSO₄, 5 mM
20 MgCl₂, and 0.1 mg/mL bovine serum albumin (BSA). PDE enzyme was present in quantities that yield <30% total hydrolysis of substrate (linear assay conditions). The assay was initiated by addition of substrate (1 mM [32P]cAMP or cGMP), and the mixture
25 was incubated for 12 minutes. Seventy-five (75) µg of Crotalus atrox venom then was added, and the incubation was continued for 3 minutes (15 minutes total). The reaction was stopped by addition of 200 µL of activated charcoal (25 mg/mL suspension in 0.1
30 M NaH₂PO₄, pH 4). After centrifugation (750 X g for 3 minutes) to sediment the charcoal, a sample of the supernatant was taken for radioactivity determina-

- 61 -

tion in a scintillation counter and the PDE activity was calculated.

Purification of PDE5 from *S. cerevisiae*

5

Cell pellets (29 g) were thawed on ice with an equal volume of Lysis Buffer (25 mM Tris HCl, pH 8, 5 mM MgCl₂, 0.25 mM DTT, 1 mM benzamidine, and 10 μM ZnSO₄). Cells were lysed in a Microfluidizer[®] (Microfluidics Corp.) using nitrogen at 20,000 psi. The lysate was centrifuged and filtered through 0.45 μm disposable filters. The filtrate was applied to a 150 mL column of Q SEPHAROSE[®] Fast-Flow (Pharmacia). The column was washed with 1.5 volumes of Buffer A (20 mM Bis-Tris Propane, pH 6.8, 1 mM MgCl₂, 0.25 mM DTT, 10 μM ZnSO₄) and eluted with a step gradient of 125 mM NaCl in Buffer A followed by a linear gradient of 125-1000 mM NaCl in Buffer A. Active fractions from the linear gradient were applied to a 180 mL hydroxyapatite column in Buffer B (20 mM Bis-Tris Propane (pH 6.8), 1 mM MgCl₂, 0.25 mM DTT, 10 μM ZnSO₄, and 250 mM KCl). After loading, the column was washed with 2 volumes of Buffer B and eluted with a linear gradient of 0-125 mM potassium phosphate in Buffer B. Active fractions were pooled, precipitated with 60% ammonium sulfate, and resuspended in Buffer C (20 mM Bis-Tris Propane, pH 6.8, 125 mM NaCl, 0.5 mM DTT, and 10 μM ZnSO₄). The pool was applied to a 140 mL column of SEPH-ACRYL[®] S-300 HR and eluted with Buffer C. Active fractions were diluted to 50% glycerol and stored at -20°C.

30

- 62 -

The resultant preparations were about 85% pure by SDS-PAGE. These preparations had specific activities of about 3 μmol cGMP hydrolyzed per minute per milligram protein.

5

Inhibitory Effect on cGMP-PDE

cGMP-PDE activity of compounds of the present invention was measured using a one-step assay adapted from Wells et al., *Biochim. Biophys. Acta*, 384, 430 (1975). The reaction medium contained 50 mM Tris-HCl, pH 7.5, 5 mM magnesium acetate, 250 $\mu\text{g/ml}$ 5'-Nucleotidase, 1 mM EGTA, and 0.15 μM 8-[H³]-cGMP. Unless otherwise indicated, the enzyme used was a human recombinant PDE5 (ICOS Corp., Bothell, Washington).

Compounds of the invention were dissolved in DMSO finally present at 2% in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30%.

The IC₅₀ values for the compounds examined were determined from concentration-response curves typically using concentrations ranging from 10 nM to 10 μM . Tests against other PDE enzymes using standard methodology showed that compounds of the invention are selective for the cGMP-specific PDE enzyme.

Biological Data

The compounds according to the present invention were typically found to exhibit an IC₅₀ value of less than 1000 nM. An *in vitro* test data

- 63 -

for representative compounds of the invention is
given in the following table:


Table 1. <i>In vitro</i> results	
Example	PDE5 IC ₅₀ (nM)
1	3240
10	718

Obviously, many modifications and variations of the invention as hereinbefore set forth can be made without departing from the spirit and scope thereof, and, therefore, only such limitations should be imposed as are indicated by the appended claims.

- 64 -

WHAT IS CLAIMED IS:

1. A compound having a formula




wherein R^0 , independently, is selected from the group consisting of halo, C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heteroaryl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-3} alkylenearyl, C_{1-3} alkyleneheteroaryl, $C(=O)R^a$, $OC(=O)OR^a$, C_{1-4} alkylene NR^aR^b , C_{1-4} alkyleneHet, C_{1-4} alkylene $C(=O)OR^a$, $C(=O)NR^aSO_2R^b$, $C(=O)C_{1-4}$ alkyleneHet, $C(=O)NR^aR^b$, $C(=O)NR^aC_{1-4}$ alkylene OR^b , $C(=O)NR^aC_{1-4}$ alkyleneHet, OR^a , OC_{1-4} alkylene $C(=O)OR^a$, OC_{1-4} alkylene NR^aR^b , OC_{1-4} alkyleneHet, OC_{1-4} alkylene OR^a , OC_{1-4} alkylene $NR^aC(=O)OR^b$, NR^aR^b , NR^aC_{1-4} alkylene NR^aR^b , $NR^aC(=O)R^b$, $NR^aC(=O)NR^aR^b$, $N(SO_2C_{1-4}alkyl)_2$, $NR^a(SO_2C_{1-4}alkyl)$, nitro, trifluoromethyl, trifluoromethoxy, cyano, $SO_2NR^aR^b$, SO_2R^a , SOR^a , SR^a , and OSO_2CF_3 ;

R^1 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl C_{1-3} alkyl, aryl C_{1-3} alkyl, and heteroaryl C_{1-3} alkyl;

R^2 is selected from the group consisting of a monocyclic aromatic ring selected from the group consisting of benzene, thiophene, furan, and pyridine, wherein said monocyclic aromatic ring is unsubstituted or substituted with one or more of halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl; and a bicyclic ring

- 65 -



wherein the fused ring A is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur and nitrogen, and wherein said bicyclic ring is unsubstituted or substituted with one or more of halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl;

R^3 is hydrogen or C_{1-6} alkyl, or

R^1 and R^3 together form a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring;

fused ring B is a 5-, 6-, or 7-membered ring, saturated or partially or fully unsaturated, comprising carbon atoms and optionally one to three heteroatoms selected from oxygen, sulfur, and nitrogen;

R^a is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl, heteroaryl, aryl C_{1-3} alkyl, C_{1-3} alkylenearyl, $C(=O)OR^b$, $C(=O)N(R^b)_2$, C_{1-4} alkylene $N(R^b)_2$, CF_3 , OCF_3 , OR^b , $OC(=O)R^b$, OC_{1-4} alkylene $C(=O)OR^b$, C_{1-4} alkylene OC_{1-4} alkylene $C(=O)OR^b$, $C(=O)NR^bSO_2R^b$, $C(=O)C_{1-4}$ alkyleneHet, C_{2-6} alkenylen $N(R^b)_2$, $C(=O)NR^bC_{1-4}$ alkylene OR^b , $C(=O)NR^bC_{1-4}$ alkyleneHet, OC_{2-4} alkylene $N(R^b)_2$, OC_{1-4} alkylene $CH(OR^b)CH_2N(R^b)_2$, OC_{2-4} alkylene OR^b , OC_{2-4} alkylene $NR^bC(=O)OR^b$, $N(R^b)_2$, NR^bC_{1-4} alkylene $N(R^b)_2$, $NR^bC(=O)R^b$, $NR^bC(=O)N(R^b)_2$, $N(SO_2C_{1-4}alkyl)_2$, $NR^b(SO_2C_{1-4}alkyl)$, $SO_2N(R^b)_2$, OSO_2 trifluoromethyl, $C(=O)R^b$, C_{1-3} alkylene OR^b , CN, and C_{1-6} alkylene $C(=O)OR^b$;


- 66 -

R^b is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, $arylC_{1-3}$ alkyl, C_{1-3} alkylene-aryl, heteroaryl, heteroaryl C_{1-3} alkyl, and C_{1-3} alkyleneheteroaryl;

q is 0, 1, 2, 3, or 4; and

pharmaceutically acceptable salts and hydrates thereof.

2. The compound of claim 1 represented by the formula



and pharmaceutically acceptable salts thereof.

3. The compound of claim 1 wherein q is 0.


4. The compound of claim 1 wherein R^0 is selected from the group consisting of C_{1-6} alkyl, aryl, C_{1-3} alkylenearyl, C_{1-3} alkyleneheteroaryl, Het, OR^a , C_{1-4} alkylene NR^aR^b , NR^aR^b , C_{3-8} cycloalkyl and $C(=O)NR^aR^b$.

- 67 -

5. The compound of claim 1 wherein R^1 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, $haloC_{1-6}$ alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-3} alkyl, aryl C_{2-3} alkyl, and heteroaryl C_{1-3} alkyl.

6. The compound of claim 1 wherein R^2 is a bicyclic ring selected from a group consisting of naphthalene, indene, benzoxazole, benzothiazole, benzisoxazole, benzimidazole, quinoline, indole, benzothiophene, and benzofuran, and wherein said bicyclic ring is unsubstituted or substituted with one or more of halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl.



7. The compound of claim 1 wherein R^2 is




and wherein q is an integer 1 or 2, and G , independently, are $C(R^{a'})_2$, O, S, or $NR^{a'}$, wherein $R^{a'}$ is one of hydrogen, halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl.

- 68 -

8. The compound of claim 1 wherein R^2 , optionally substituted, is selected from the group consisting of



, and



- 69 -



9. The compound of claim 1 wherein the B ring is selected from the group consisting of cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, 1,3,5-cycloheptatrienyl, phenyl, furanyl, thienyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl, oxazolyl, thiazolyl, imidazolyl, 2-imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, 3H-pyrrolyl, 1,2-dithiolyl, 1,3-dithiolyl, 3H-1,2-oxathiolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3,4-oxatriazolyl, 1,2,3,5-oxatriazolyl, 3H-1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2-dioxazolyl, 1,3,4-dioxazolyl, 5H-1,2,5-oxathiazolyl, 1,3-oxathiolyl, 2H-pyranyl, 4H-pyranyl, pyridinyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, 2-pyrronyl, 4-pyrronyl, 1,2-dioxinyl, 1,3-dioxinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 4H-1,3-oxadiazinyl, 6H-1,2-oxazinyl, 2H-1,3-oxazinyl, 6H-1,3-oxazinyl, 2H-1,2-oxazinyl, 4H-1,4-oxazinyl, 1,2,5-oxathiazinyl, 1,4-oxazinyl, o-isoxazinyl, p-isoxazinyl, 1,2,6-oxathiazinyl, 1,4,2-oxadiazinyl, 1,3,5,2-oxadiazinyl, azepinyl, oxepinyl, thiopinyl, and 1,2,4-diazepinyl.

-70-



10. The compound of claim 9 wherein the B ring is selected from the group consisting of phenyl, imidazolyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, piperidinyl, cyclohexyl, pyrimidinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, piperazinyl, and 2-imidazolinyl.

- 71 -


11. A compound selected from the group consisting of






- 72 -





wherein X=O or S



- 73 -



- 74 -



and pharmaceutically acceptable salts thereof.

12. A pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.

13. Use of an effective amount of a pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier for treatment of a male or female animal for a condition wherein inhibition of a cGMP-specific PDE5 is of therapeutic benefit.

-75-

14. The use of claim 13 wherein the condition is male erectile dysfunction.

15. The use of claim 14 wherein the treatment is an oral treatment.

16. The use of claim 13 wherein the condition is female arousal disorder.

17. The use of claim 16 wherein the treatment is an oral treatment.

18. The use of claim 13 wherein the condition is selected from the group consisting of stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, malignant hypertension, pheochromocytoma, acute respiratory distress syndrome, congestive heart failure, acute renal failure, chronic renal failure, atherosclerosis, a condition of reduced blood vessel patency, a peripheral vascular disease, a vascular disorder, thrombocythemia, an inflammatory disease, myocardial infarction, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, a gut motility disorder, postpercutaneous transluminal coronary angioplasty, carotid angioplasty, post bypass surgery graft stenosis, osteoporosis, preterm labor, benign prostatic hypertrophy, and irritable bowel syndrome.

-76-

19. Use of a therapeutically effective amount of a compound of claim 1 for treatment of a condition wherein inhibition of a cGMP-specific PDE5 is of therapeutic benefit in a human or non-human animal.

20. Use of an effective dose of a compound of claim 1, and pharmaceutically effective salts thereof for curative or prophylactic treatment of male erectile dysfunction or female arousal disorder in an animal, wherein inhibition of a cGMP-specific PDE5 is of therapeutic benefit.

21. Use of a compound of claim 1 for the manufacture of a medicament for the curative or prophylactic treatment of a condition wherein inhibition of a cGMP-specific PDE5 is of a therapeutic benefit.

